CN1358094A - 用mek抑制剂治疗慢性疼痛的方法 - Google Patents

用mek抑制剂治疗慢性疼痛的方法 Download PDF

Info

Publication number
CN1358094A
CN1358094A CN00809478A CN00809478A CN1358094A CN 1358094 A CN1358094 A CN 1358094A CN 00809478 A CN00809478 A CN 00809478A CN 00809478 A CN00809478 A CN 00809478A CN 1358094 A CN1358094 A CN 1358094A
Authority
CN
China
Prior art keywords
methyl
phenyl
fluoro
alkyl
iodo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00809478A
Other languages
English (en)
Chinese (zh)
Inventor
S·D·巴瑞特
A·J·布里德格斯
H·泰克
A·迪克森
K·利
R·D·皮诺可
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of CN1358094A publication Critical patent/CN1358094A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN00809478A 1999-07-16 2000-07-05 用mek抑制剂治疗慢性疼痛的方法 Pending CN1358094A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14441899P 1999-07-16 1999-07-16
US60/144,418 1999-07-16

Publications (1)

Publication Number Publication Date
CN1358094A true CN1358094A (zh) 2002-07-10

Family

ID=22508500

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00809478A Pending CN1358094A (zh) 1999-07-16 2000-07-05 用mek抑制剂治疗慢性疼痛的方法

Country Status (13)

Country Link
EP (1) EP1202731A2 (ko)
JP (1) JP2003504398A (ko)
KR (1) KR20020015376A (ko)
CN (1) CN1358094A (ko)
AU (1) AU6068600A (ko)
CA (1) CA2377092A1 (ko)
CO (1) CO5190704A1 (ko)
HU (1) HUP0202319A3 (ko)
IL (1) IL147150A0 (ko)
PE (1) PE20010546A1 (ko)
PL (1) PL352835A1 (ko)
WO (1) WO2001005390A2 (ko)
ZA (1) ZA200109906B (ko)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101486682B (zh) * 2002-03-13 2013-08-14 阵列生物制药公司 作为mek抑制剂的n3烷基化苯并咪唑衍生物
CN104774188A (zh) * 2014-01-15 2015-07-15 江苏恒瑞医药股份有限公司 苯并杂环类或苯并杂芳环类衍生物、其制备方法及其在医药上的应用
CN109336824A (zh) * 2012-10-19 2019-02-15 诺华股份有限公司 Mek抑制剂的制备和包含mek抑制剂的制剂
CN114788867A (zh) * 2022-04-24 2022-07-26 天津医科大学总医院 Map2k1作为化疗后神经痛的治疗靶点的应用

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035971A1 (es) 2001-05-16 2004-07-28 Cephalon Inc Metodos para el tratamiento y la prevencion del dolor
AU2002310441A1 (en) * 2001-06-14 2003-01-02 The Regents Of The University Of California A novel signaling pathway for the production of inflammatory pain and neuropathy
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
JP2005526076A (ja) * 2002-03-13 2005-09-02 アレイ バイオファーマ、インコーポレイテッド Ｍｅｋ阻害剤としてのｎ３アルキル化ベンズイミダゾール誘導体
GB0213383D0 (en) * 2002-06-11 2002-07-24 Cambridge Biotechnology Ltd Therapeutic conditions
US20050004186A1 (en) * 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
DE602004023207D1 (de) * 2003-07-24 2009-10-29 Warner Lambert Co Benzimidazol-derivate als mek-hemmer
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
BRPI0414581C1 (pt) 2003-09-22 2021-05-25 Mei Pharma Inc composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
US7598383B2 (en) 2003-11-19 2009-10-06 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
KR101223914B1 (ko) 2003-11-21 2013-01-18 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제
CN102942522A (zh) 2005-05-18 2013-02-27 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
AR054623A1 (es) 2005-06-23 2007-07-04 Astrazeneca Ab PROCESO PARA PREPARAR DERIVADOS DE BENCIMIDAZOL Y COMPUESTOS INTERMEDIARIOS DE SíNTESIS DE LOS MISMOS.
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
JP5231411B2 (ja) 2006-07-06 2013-07-10 アレイ バイオファーマ、インコーポレイテッド Ａｋｔプロテインキナーゼ阻害剤としてのジヒドロチエノピリミジン
EP2049500B1 (en) 2006-07-06 2011-09-07 Array Biopharma, Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
WO2008006025A1 (en) 2006-07-06 2008-01-10 Array Biopharma Inc. Dihydrofuro pyrimidines as akt protein kinase inhibitors
AU2007334402B2 (en) 2006-12-14 2014-02-13 Exelixis, Inc. Methods of using MEK inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
RU2486181C2 (ru) 2007-07-05 2013-06-27 Эррэй Биофарма Инк. Пиримидилциклопентаны как ингибиторы акт-протеинкиназ
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
SI2173723T1 (sl) 2007-07-05 2011-12-30 Array Biopharma Inc Pirimidil ciklopentani kot inhibitorji AKT-protein-kinaze
AU2008343062B2 (en) 2007-12-19 2013-03-07 Genentech, Inc. 8-Anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
RU2441004C1 (ru) 2007-12-19 2012-01-27 Дженентек, Инк. 5-анилиноимидазопиридины и способы их применения
AU2008340247B2 (en) 2007-12-21 2012-11-15 Genentech, Inc. Azaindolizines and methods of use
ES2401685T3 (es) 2008-01-09 2013-04-23 Array Biopharma, Inc. Pirimidil ciclopentano hidroxilado como inhibidor de la proteína quinasa AKT
KR101624753B1 (ko) 2008-01-09 2016-05-26 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 저해물질로서의 수산화된 피리미딜 시클로펜탄
MX2010014565A (es) 2008-07-01 2011-03-04 Genentech Inc Isoindolona y metodos de uso.
EP2346818B1 (en) 2008-11-10 2012-12-05 Bayer Intellectual Property GmbH Substituted sulphonamido phenoxybenzamides
WO2011047795A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides
US20120263714A1 (en) 2009-10-21 2012-10-18 Bayer Intellectual Property Gmbh Substituted halophenoxybenzamide derivatives
CN102656142A (zh) 2009-10-21 2012-09-05 拜耳制药股份公司 取代的苯磺酰胺
CA2816188A1 (en) 2010-10-29 2012-05-03 Marion Hitchcock Substituted phenoxypyridines
MX2013011333A (es) 2011-04-01 2014-04-16 Genentech Inc Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso.
ES2620644T3 (es) 2011-04-01 2017-06-29 Genentech, Inc. Combinaciones de compuestos inhibidores de AKT y agentes quimioterapéuticos, y métodos de uso
ES2396764B1 (es) 2011-11-02 2013-12-19 Universidad Autónoma de Madrid FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES.
SG11201402660YA (en) 2011-12-21 2014-10-30 Novira Therapeutics Inc Hepatitis b antiviral agents
CN103204825B (zh) 2012-01-17 2015-03-04 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途
KR102122244B1 (ko) 2012-08-28 2020-06-15 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도
MY186549A (en) 2012-10-12 2021-07-26 Exelixis Inc Novel process for making compounds for use in the treatment of cancer
AU2014222641B2 (en) 2013-02-28 2018-03-15 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
MX353412B (es) 2013-04-03 2018-01-10 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
CN108047115B (zh) 2013-07-25 2021-06-29 爱尔兰詹森科学公司 经乙醛酰胺取代的吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
EA034448B1 (ru) 2013-10-23 2020-02-10 Янссен Сайенсиз Айрлэнд Юси Производные карбоксамида и их применение в качестве медикаментов для лечения гепатита b
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
KR20160128305A (ko) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Hbv 감염의 치료를 위한 병용 요법
US11078193B2 (en) 2014-02-06 2021-08-03 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
US9884831B2 (en) 2015-03-19 2018-02-06 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN108430971A (zh) 2015-09-29 2018-08-21 诺维拉治疗公司 乙型肝炎抗病毒剂的晶体形式
AU2017248828A1 (en) 2016-04-15 2018-11-01 Janssen Sciences Ireland Uc Combinations and methods comprising a capsid assembly inhibitor
AR108257A1 (es) 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
CN111867582A (zh) 2018-03-14 2020-10-30 爱尔兰詹森科学公司 衣壳组装调节剂给药方案
CA3127152A1 (en) 2019-02-22 2020-08-27 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
CA3132554A1 (en) 2019-05-06 2020-11-12 Bart Rudolf Romanie Kesteleyn Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
CN110981819B (zh) * 2019-12-24 2022-07-01 广西师范大学 一种喹喔啉类信号通路抑制剂及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251943B1 (en) * 1997-02-28 2001-06-26 Warner-Lambert Company Method of treating or preventing septic shock by administering a MEK inhibitor
CA2355470C (en) * 1999-01-13 2008-09-30 Warner-Lambert Company Benzoheterocycles and their use as mek inhibitors

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101486682B (zh) * 2002-03-13 2013-08-14 阵列生物制药公司 作为mek抑制剂的n3烷基化苯并咪唑衍生物
CN109336824A (zh) * 2012-10-19 2019-02-15 诺华股份有限公司 Mek抑制剂的制备和包含mek抑制剂的制剂
CN104774188A (zh) * 2014-01-15 2015-07-15 江苏恒瑞医药股份有限公司 苯并杂环类或苯并杂芳环类衍生物、其制备方法及其在医药上的应用
CN104774188B (zh) * 2014-01-15 2019-10-11 江苏恒瑞医药股份有限公司 苯并杂环类或苯并杂芳环类衍生物、其制备方法及其在医药上的应用
CN114788867A (zh) * 2022-04-24 2022-07-26 天津医科大学总医院 Map2k1作为化疗后神经痛的治疗靶点的应用

Also Published As

Publication number Publication date
CA2377092A1 (en) 2001-01-25
AU6068600A (en) 2001-02-05
EP1202731A2 (en) 2002-05-08
HUP0202319A2 (en) 2002-10-28
ZA200109906B (en) 2003-05-28
JP2003504398A (ja) 2003-02-04
HUP0202319A3 (en) 2004-12-28
PL352835A1 (en) 2003-09-08
KR20020015376A (ko) 2002-02-27
WO2001005390A2 (en) 2001-01-25
CO5190704A1 (es) 2002-08-29
WO2001005390A3 (en) 2001-05-17
IL147150A0 (en) 2002-08-14
PE20010546A1 (es) 2001-06-04

Similar Documents

Publication Publication Date Title
CN1358094A (zh) 用mek抑制剂治疗慢性疼痛的方法
CN1287487A (zh) 氨基苯氧基乙酸衍生物和含有它们的药用组合物
CN1243723C (zh) 作为fsad的nep抑制剂的n－苯丙基环戊基取代的戊二酰胺衍生物
CN1148183C (zh) 具有抗肿瘤作用的吲哚基-3-乙醛酸衍生物
CN1028104C (zh) 制备喹诺酮衍生物的方法
CN1116288C (zh) 用作肌苷－5'－一磷酸脱氢酶抑制剂的脲衍生物
CN1237052C (zh) 用作钾通道抑制剂的邻位取代的含氮双芳基化合物
CN1094490C (zh) 作为血清素拮抗剂的喹诺－2(1h)－酮衍生物
CN1309711C (zh) 3－酰氨基－1,2－苯并异噁唑衍生物、其制备方法及应用
CN1365277A (zh) 使用mek抑制剂治疗慢性疼痛的方法
CN1255493A (zh) 新的二氢和四氢喹啉化合物,其制备方法及其药物组合物
CN1040985C (zh) 苯并氮杂䓬类化合物的制备方法
CN1496980A (zh) 具有抗哮喘、抗过敏和免疫抑制/免疫调节作用的n-取代的吲哚-3-乙醛酰胺类化合物
CN1187188A (zh) 旋转异构酶活性的小分子抑制剂
CN1909897A (zh) 用于治疗阿尔茨海默病的苯基羧化物β－分泌酶抑制剂
CN1479734A (zh) 具有钾通道阻断作用的芳基化呋喃和噻吩甲酰胺
CN1234797A (zh) N－取代的氮杂环化合物
CN1104422C (zh) 用作α－2肾上腺素能受体兴奋剂的胍基杂环化合物
CN1230174C (zh) 治疗偏头痛的选择性iGluR5受体拮抗剂
CN1036064C (zh) 新的具有ngf生成促进活性的苯衍生物的制备方法
CN1032534C (zh) 二氨基三氟甲基吡啶衍生物的制备方法
CN1336915A (zh) N－杂环羧酸或羧酸等排物的脲和氨基羧酸酯
CN1294578A (zh) 新的萘基和酰苯胺取代的磺酰胺
CN1930151A (zh) 将dna的特定碱基序列烷基化的新吲哚衍生物和使用其的烷基化剂以及药剂
CN1139572C (zh) Nmda(n-甲基-d-天冬氨酸)拮抗剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1047233

Country of ref document: HK